Scientific article

Ostéonécrose des maxillaires et bisphosphonates

Published inRevue médicale suisse, vol. 1, no. 39, p. 2537-2540,2542-3
Publication date2005

Widely prescribed, bisphosphonates inhibit bone resorption. They are not metabolised and have long half-lives. Two cases of osteonecrosis of the jaws have recently been attributed to bisphosphonates at the University Hospital of Geneva. The recent literature reveals more than a hundred similar cases throughout the world. Bone exposure appears spontaneously or after dental care. Treatment of the osteonecrosis is controversial and cure very difficult. This pathology is usually seen in patients on chemotherapy, steroids and i.v. bisphosphonates, but is sometimes seen with low-dose p.o. bisphosphonates. In view of the strong association between bisphosphonate therapy and osteonecrosis of the jaw, specialists have recommended dental and oral evaluation during bisphosphonate therapy as well as for several years after drug discontinuation.

  • Age Factors
  • Diphosphonates/administration & dosage/adverse effects/therapeutic use
  • Drug Interactions
  • Humans
  • Infusions, Intravenous
  • Jaw/pathology
  • Osteonecrosis/chemically induced
  • Steroids/therapeutic use
Citation (ISO format)
JUNOD, Alain et al. Ostéonécrose des maxillaires et bisphosphonates. In: Revue médicale suisse, 2005, vol. 1, n° 39, p. 2537–2540,2542–3.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation08/18/2014 2:55:00 PM
First validation08/18/2014 2:55:00 PM
Update time03/14/2023 9:31:48 PM
Status update03/14/2023 9:31:48 PM
Last indexation01/16/2024 11:37:25 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack